Comparative effects of aspirin and ibuprofen in the management of systemic lupus erythematosus

Jacob Karsh(Ottawa Hospital), John L. Decker(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Robert P. Kimberly(Regeneron (United States)), Paul H. Plötz(National Institutes of Health), Neil Stahl(Arthritis and Rheumatism Associates)
Arthritis & Rheumatism
December 1, 1980
10.1002/art.1780231215
Cited by 23

Related Papers

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Therapy of Lupus Nephritis
|New England Journal of Medicine|1986|1.2k
A New Approach to the Classification of Idiopathic Inflammatory Myopathy
|Medicine|1991|974
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
|The Lancet|2015|566
Defective Reticuloendothelial System Fc-Receptor Function in Systemic Lupus Erythematosus
|New England Journal of Medicine|1979|531